BIIB Share Price

Open 282.18 Change Price %
High 284.32 1 Day -0.51 -0.18
Low 280.75 1 Week 0.63 0.22
Close 281.44 1 Month 2.84 1.02
Volume 1044956 1 Year -1.01 -0.36
52 Week High 333.65
52 Week Low 244.28
BIIB Important Levels
Resistance 2 284.75
Resistance 1 283.39
Pivot 282.17
Support 1 279.49
Support 2 278.13
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
More..
NASDAQ USA Top Gainers Stocks
SCHS 0.05 66.67%
CPWR 4.65 55.00%
LOCM 0.09 50.00%
VRTB 3500.00 33.33%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
SRPT 40.93 20.10%
AEZS 2.80 19.66%
GEVO 0.71 18.33%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
QKLS 0.11 -47.62%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Biogen Idec Inc. (NASDAQ: BIIB)

BIIB Technical Analysis 2
As on 20th Jul 2017 BIIB Share Price closed @ 281.44 and we RECOMMEND Sell for LONG-TERM with Stoploss of 284.76 & Strong Buy for SHORT-TERM with Stoploss of 264.20 we also expect STOCK to react on Following IMPORTANT LEVELS.
BIIB Target for July
1st Target up-side 290.9
2nd Target up-side 304.59
3rd Target up-side 318.29
1st Target down-side 251.82
2nd Target down-side 238.13
3rd Target down-side 224.43
BIIB Other Details
Segment EQ
Market Capital 33194547200.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.biogenidec.com
BIIB Address
BIIB
225 Binney Street
Cambridge, MA 02142
United States
Phone: 781-464-2000
BIIB Latest News
Interactive Technical Analysis Chart Biogen Idec Inc. ( BIIB NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Biogen Idec Inc.
BIIB Business Profile
Biogen Idec Inc. (Biogen Idec) is a global biotechnology company. The Company discovers, develops, manufactures and markets therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. The Company’s products include AVONEX, TYSABRI, FAMPYRA, FUMADERM and RITUXAN. In September 2011, the Company acquired from the Dompe Group the noncontrolling interests in its joint venture sales affiliates in Italy and Switzerland. In April 2013, Elan Corporation, plc closed the TYSABRI (natalizumab) Collaboration Transaction with Biogen Idec.